Kirsten rat sarcoma-2 virus oncogene (KRAS), also known as c-K-Ras, is encoded by the gene mapped to human chromosome 12p12.1. It is a small GTP-binding protein. Alternative splicing of this gene results in two variants namely, KRASA and KRASB (KRAS proto-oncogenes). Expression of KRASA is restricted to specific tissues, whereas KRASB is ubiquitously expressed.
Synonyms: Anti-KRAS1; Anti-KRAS2
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Kirsten rat sarcoma-2 virus oncogene (KRAS) plays a vital role in signaling pathways. Mutation in the gene is associated with the development of early rectal cancer and colorectal cancer (CRC). Thus, it acts as a potential predictive biomarker in CRC.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC